Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | CXCR4 | P61073 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.61 |
| ▸ | FAAH | O00519 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28910476 | 0.86 | CXCR4 (0.61) | POLBCXCR4ALDH1A1ATMSIGMAR1 | |
| SCHEMBL23673413 | 0.85 | POLB (0.50) | POLBCXCR4ALDH1A1ATMSIGMAR1 | |
| SCHEMBL29783875 | 0.85 | POLB (0.50) | POLBCXCR4ALDH1A1ATMSIGMAR1 | |
| SCHEMBL28534607 | 0.84 | CXCR4 (0.58) | POLBCXCR4ALDH1A1ATMSIGMAR1 | |
| SCHEMBL28543178 | 0.84 | CXCR4 (0.58) | POLBCXCR4ALDH1A1ATMSIGMAR1 | |
| SCHEMBL2070462 | 0.84 | EPHX2 (0.67) | SIGMAR1CYP2A13 | |
| SCHEMBL1519223 | 0.83 | MEN1 (0.69) | SIGMAR1FAAHL3MBTL1MEN1KMT2A | |
| SCHEMBL30377416 | 0.83 | ALDH1A1 (0.62) | POLBALDH1A1ATMSIGMAR1KDM4E | |
| Hydrochloric Acid SCHEMBL2551741 | 0.82 | MEN1 (0.68) | SIGMAR1FAAHL3MBTL1MEN1KMT2A | |
| SCHEMBL8551996 | 0.82 | CXCR4 (0.69) | POLBCXCR4ALDH1A1ATMSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059979-A1 | Piperidine/Cyclohexane Carboxamide Derivatives For Use as Vanilloid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
| EP-1660481-A1 | PIPERIDINE/CYCLOHEXANE CARBOXAMIDE DERIVATIVES FOR USE AS VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005016915-A1 | PIPERIDINE/CYCLOHEXANE CARBOXAMIDE DERIVATIVES FOR USE AS VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059979-A1 | Piperidine/Cyclohexane Carboxamide Derivatives For Use as Vanilloid Receptor Modulators | TRPV1, CNR1, OPRM1 | POLB 3992/4885CXCR4 486/4885ALDH1A1 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.